TO THE EDITOR:
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells have revolutionized the treatment for patients with relapsed and refractory multiple myeloma, with 2 US Food and Drug Administration–approved products, idecabtagene vicleucel and ciltacabtagene autoleucel (cilta-cel).1,2 Follow-up of patients receiving cilta-cel in the CARTITUDE-1 study found 82.5% of patients achieved a stringent complete response,3 with a median progression-free survival of 34.9 months.4 However, in addition to common complications, like cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and prolonged cytopenia seen with other CAR products,5-9 movement and neurocognitive toxicities (MNTs) have also developed in patients receiving BCMA-targeting CARs.1,3,10 MNTs occurred in 6% of patients treated in CARTITUDE-1, but they have been less frequent in the more recent cilta-cel trials.3,11 Risk factors for...
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal